Allena Pharmaceuticals’ (ALNA) “Outperform” Rating Reaffirmed at Credit Suisse Group

Credit Suisse Group restated their outperform rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a research note issued to investors on Monday, BenzingaRatingsTable reports. Credit Suisse Group currently has a $26.00 target price on the stock.

Other analysts have also issued reports about the company. Cowen reaffirmed a buy rating on shares of Allena Pharmaceuticals in a report on Friday, May 10th. Zacks Investment Research lowered Allena Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 30th. Wedbush reaffirmed a buy rating and set a $36.00 target price on shares of Allena Pharmaceuticals in a report on Tuesday, July 2nd. Finally, ValuEngine raised Allena Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Allena Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $21.83.

Allena Pharmaceuticals stock opened at $3.97 on Monday. The firm has a market capitalization of $82.01 million, a price-to-earnings ratio of -2.31 and a beta of 1.98. Allena Pharmaceuticals has a 52 week low of $3.72 and a 52 week high of $12.38. The business’s 50-day moving average is $4.54. The company has a debt-to-equity ratio of 0.24, a quick ratio of 7.83 and a current ratio of 7.83.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). On average, sell-side analysts anticipate that Allena Pharmaceuticals will post -2.06 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Wedbush Securities Inc. bought a new stake in Allena Pharmaceuticals during the 2nd quarter worth approximately $63,000. Sphera Funds Management LTD. grew its holdings in Allena Pharmaceuticals by 24.9% during the 1st quarter. Sphera Funds Management LTD. now owns 431,193 shares of the company’s stock worth $3,027,000 after acquiring an additional 85,994 shares during the last quarter. Deutsche Bank AG grew its holdings in Allena Pharmaceuticals by 8.2% during the 4th quarter. Deutsche Bank AG now owns 28,023 shares of the company’s stock worth $151,000 after acquiring an additional 2,118 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Allena Pharmaceuticals by 3.8% during the 4th quarter. Squarepoint Ops LLC now owns 43,500 shares of the company’s stock worth $237,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Allena Pharmaceuticals by 8.1% during the 4th quarter. Geode Capital Management LLC now owns 72,314 shares of the company’s stock worth $394,000 after acquiring an additional 5,444 shares during the last quarter. 79.70% of the stock is currently owned by hedge funds and other institutional investors.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Recommended Story: Why do companies pay special dividends?

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.